Home European Commission Grants Marketing Authorization for Gilead's...
 

Keywords :   


European Commission Grants Marketing Authorization for Gilead's...

2014-11-19 12:58:48| Biotech - Topix.net

Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for Harvoni , the first once-daily single tablet regimen to treat the majority of chronic hepatitis C genotype 1 and 4 infection in adults. Harvoni combines the NS5A inhibitor ledipasvir with the nucleotide analog polymerase inhibitor sofosbuvir , approved by the European Commission under the tradename Sovaldi in January 2014.

Tags: marketing european commission grants

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
01.11CERM launches new MIS products, Mark Andy innovates and more
01.11Getting more out of fall and winter grazing
01.11U.S. Boston butt burger launches in Colombia
01.11All Americans have a role in keeping African swine fever out
01.11BASF TotalEnergies Petrochemicals Receives United Way Champions of Hope Award
01.11US jobs growth slows as presidential election looms
01.11Heritage Environmental Services Secures Commercial Permit Status for Orange, TX Incinerator
01.11Value for Money tsar linked to string of overspends
More »